Gene therapy for muscular dystrophy: current progress and future prospects

Bibliography

• Judge LM, Haraguchiln M, Chamberlain JS. Dissecting the signaling and mechanical functions of the dystrophin-glycoprotein complex. J Cell Sci 2006;119(Pt 8):1537-46
   PubMed Web of Science ®Google Scholar
• Mcnally EM, Pytel P. Muscle diseases: the muscular dystrophies. Annu Rev Pathol 2007;2:87-109
   PubMed Web of Science ®Google Scholar
• Straub V, Bushby K. Therapeutic possibilities in the autosomal recessive limb-girdle muscular dystrophies. Neurotherapeutics 2008;5(4):619-26
   PubMed Web of Science ®Google Scholar
• Muntoni F, Torelli S, Brockington M. Muscular dystrophies due to glycosylation defects. Neurotherapeutics 2008;5(4):627-32
   PubMed Web of Science ®Google Scholar
• Beckmann JS, Spencer M. Calpain 3, the “gatekeeper” of proper sarcomere assembly, turnover and maintenance. Neuromuscul Disord 2008;18(12):913-21
   PubMed Web of Science ®Google Scholar
• Wheeler MA, Ellis JA. Molecular signatures of Emery-Dreifuss muscular dystrophy. Biochem Soc Trans 2008;36(Pt 6):1354-8
   PubMed Web of Science ®Google Scholar
• Brown SC, Piercy RJ, Muntoni F, Sewry CA. Investigating the pathology of Emery-Dreifuss muscular dystrophy. Biochem Soc Trans 2008;36(Pt 6):1335-8
   PubMed Web of Science ®Google Scholar
• Brais B. Oculopharyngeal muscular dystrophy: a polyalanine myopathy. Curr Neurol Neurosci Rep 2009;9(1):76-82
   PubMed Web of Science ®Google Scholar
• Kaliman P, Llagostera E. Myotonic dystrophy protein kinase (DMPK) and its role in the pathogenesis of myotonic dystrophy 1. Cell Signal 2008;20(11):1935-41
   PubMed Web of Science ®Google Scholar
• Kawano R, Ishizaki M, Maeda Y, et al. Transduction of full-length dystrophin to multiple skeletal muscles improves motor performance and life span in utrophin/dystrophin double knockout mice. Mol Ther 2008;16(5):825-31
   PubMed Web of Science ®Google Scholar
• Deol JR, Danialou G, Larochelle N, et al. Successful compensation for dystrophin deficiency by a helper-dependent adenovirus expressing full-length utrophin. Mol Ther 2007;15(10):1767-74
   PubMed Web of Science ®Google Scholar
• Uchida Y, Maeda Y, Kimura E, et al. Effective repetitive dystrophin gene transfer into skeletal muscle of adult mdx mice using a helper-dependent adenovirus vector expressing the coxsackievirus and adenovirus receptor (CAR) and dystrophin. J Gene Med 2005;7(8):1010-22
   PubMed Web of Science ®Google Scholar
• Gao GP, Alvira MR, Wang L, et al. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci USA 2002;99(18):11854-9
   PubMed Web of Science ®Google Scholar
• Louboutin JP, Wang L, Wilson JM. Gene transfer into skeletal muscle using novel AAV serotypes. J Gene Med 2005;7(4):442-51
   PubMed Web of Science ®Google Scholar
• Vitiello C, Faraso S, Sorrentino NC, et al. Disease rescue and increased lifespan in a model of cardiomyopathy and muscular dystrophy by combined AAV treatments. PLoS ONE 2009;4(3):e5051. Published online 31 March 2009, doi:10.1371/journal.pone.0005051
   PubMed Web of Science ®Google Scholar
• Lai Y, Thomas GD, Yue Y, et al. Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy. J Clin Invest 2009;119(3):624-35
   PubMed Web of Science ®Google Scholar
• Martin PT, Xu R, Rodino-Klapac LR, et al. Overexpression of Galgt2 in skeletal muscle prevents injury resulting from eccentric contractions in both mdx and wild-type mice. Am J Physiol Cell Physiol 2009;296(3):C476-88
   PubMed Web of Science ®Google Scholar
• Odom GL, Gregorevic P, Chamberlain JS. Viral-mediated gene therapy for the muscular dystrophies: successes, limitations and recent advances. Biochim Biophys Acta 2007;1772(2):243-62
   PubMed Web of Science ®Google Scholar
• Trollet C, Bloquel C, Scherman D, Bigey P. Electrotransfer into skeletal muscle for protein expression. Curr Gene Ther 2006;6(5):561-78
   PubMed Web of Science ®Google Scholar
• Molnar MJ, Gilbert R, Lu Y, et al. Factors influencing the efficacy, longevity, and safety of electroporation-assisted plasmid-based gene transfer into mouse muscles. Mol Ther 2004;10(3):447-55
   PubMed Web of Science ®Google Scholar
• Kapsa R, Kornberg AJ, Byrne E. Novel therapies for Duchenne muscular dystrophy. Lancet Neurol 2003;2(5):299-310
   PubMed Web of Science ®Google Scholar
• Zhang G, Budker V, Williams P, et al. Efficient expression of naked DNA delivered intraarterially to limb muscles of nonhuman primates. Hum Gene Ther 2001;12(4):427-38
   PubMed Web of Science ®Google Scholar
• Hagstrom JE, Hegge J, Zhang G, et al. A facile nonviral method for delivering genes and siRNAs to skeletal muscle of mammalian limbs. Mol Ther 2004;10(2):386-98
   PubMed Web of Science ®Google Scholar
• Wolff JA, Budker V. The mechanism of naked DNA uptake and expression. Adv Genet 2005;54:3-20
   PubMed Web of Science ®Google Scholar
• Banks GB, Chamberlain JS, Froehner SC. Truncated dystrophins can influence neuromuscular synapse structure. Mol Cell Neurosci 2009;40(4):433-41
   PubMed Web of Science ®Google Scholar
• Gregorevic P, Allen JM, Minami E, et al. rAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice. Nat Med 2006;12(7):787-9
   PubMed Web of Science ®Google Scholar
• Townsend D, Blankinship MJ, Allen JM, et al. Systemic administration of micro-dystrophin restores cardiac geometry and prevents dobutamine-induced cardiac pump failure. Mol Ther 2007;15(6):1086-92
   PubMed Web of Science ®Google Scholar
• Athanasopoulos T, Graham IR, Foster H, Dickson G. Recombinant adeno-associated viral (rAAV) vectors as therapeutic tools for Duchenne muscular dystrophy (DMD). Gene Ther 2004;11(Suppl 1):S109-21
   PubMedGoogle Scholar
• Bostick B, Yue Y, Lai Y, et al. Adeno-associated virus serotype-9 microdystrophin gene therapy ameliorates electrocardiographic abnormalities in mdx mice. Hum Gene Ther 2008;19(8):851-6
   PubMed Web of Science ®Google Scholar
• Odom GL, Gregorevic P, Allen JM, et al. Microutrophin delivery through rAAV6 increases lifespan and improves muscle function in dystrophic dystrophin/utrophin-deficient mice. Mol Ther 2008;16(9):1539-45
   PubMed Web of Science ®Google Scholar
• Foster H, Sharp PS, Athanasopoulos T, et al. Codon and mRNA sequence optimization of microdystrophin transgenes improves expression and physiological outcome in dystrophic mdx mice following AAV2/8 gene transfer. Mol Ther 2008;16(11):1825-32
   PubMed Web of Science ®Google Scholar
• Salva MZ, Himeda CL, Tai PW, et al. Design of tissue-specific regulatory cassettes for high-level rAAV-mediated expression in skeletal and cardiac muscle. Mol Ther 2007;15(2):320-9
   PubMed Web of Science ®Google Scholar
• Wang B, Li J, Fu FH, et al. Construction and analysis of compact muscle-specific promoters for AAV vectors. Gene Ther 2008;15(22):1489-99
   PubMed Web of Science ®Google Scholar
• Lai Y, Yue Y, Liu M, et al. Efficient in vivo gene expression by trans-splicing adeno-associated viral vectors. Nat Biotechnol 2005;23(11):1435-9
   PubMed Web of Science ®Google Scholar
• Ghosh A, Yue Y, Lai Y, Duan D. A hybrid vector system expands adeno-associated viral vector packaging capacity in a transgene-independent manner. Mol Ther 2008;16(1):124-30
   PubMed Web of Science ®Google Scholar
• Li J, Sun W, Wang B, et al. Protein trans-splicing as a means for viral vector-mediated in vivo gene therapy. Hum Gene Ther 2008;19(9):958-64
   PubMed Web of Science ®Google Scholar
• Mcclorey G, Moulton HM, Iversen PL, et al. Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD. Gene Ther 2006;13(19):1373-81
   PubMed Web of Science ®Google Scholar
• Alter J, Lou F, Rabinowitz A, et al. Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nat Med 2006;12(2):175-7
   PubMed Web of Science ®Google Scholar
• Bremmer-Bout M, Aartsma-Rus A, de Meijer EJ, et al. Targeted exon skipping in transgenic hDMD mice: A model for direct preclinical screening of human-specific antisense oligonucleotides. Mol Ther 2004;10(2):232-40
   PubMed Web of Science ®Google Scholar
• Graham IR, Hill VJ, Manoharan M, et al. Towards a therapeutic inhibition of dystrophin exon 23 splicing in mdx mouse muscle induced by antisense oligoribonucleotides (splicomers): target sequence optimisation using oligonucleotide arrays. J Gene Med 2004;6(10):1149-58
   PubMed Web of Science ®Google Scholar
• Lu QL, Rabinowitz A, Chen YC, et al. Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles. Proc Natl Acad Sci USA 2005;102(1):198-203
   PubMed Web of Science ®Google Scholar
• Yokota T, Lu QL, Partridge T, et al. Efficacy of systemic morpholino exon-skipping in Duchenne dystrophy dogs. Ann Neurol 2009; [Epub ahead of print]
   PubMedGoogle Scholar
• Arechavala-Gomeza V, Graham IR, Popplewell LJ, et al. Comparative analysis of antisense oligonucleotide sequences for targeted skipping of exon 51 during dystrophin pre-mRNA splicing in human muscle. Hum Gene Ther 2007;18(9):798-810
   PubMed Web of Science ®Google Scholar
• Aartsma-Rus A, Fokkema I, Verschuuren J, et al. Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations. Hum Mutat 2009;30(3):293-9
   PubMed Web of Science ®Google Scholar
• Popplewell LJ, Trollet C, Dickson G, Graham IR. Design of phosphorodiamidate morpholino oligomers (PMOs) for the induction of exon skipping of the human DMD gene. Mol Ther 2009;17(3):554-61
   PubMed Web of Science ®Google Scholar
• Wilton SD, Fall AM, Harding PL, et al. Antisense oligonucleotide-induced exon skipping across the human dystrophin gene transcript. Mol Ther 2007;15(7):1288-96
   PubMed Web of Science ®Google Scholar
• Takeshima Y, Yagi M, Wada H, et al. Intravenous infusion of an antisense oligonucleotide results in exon skipping in muscle dystrophin mRNA of Duchenne muscular dystrophy. Pediatr Res 2006;59(5):690-4
   PubMed Web of Science ®Google Scholar
• van Deutekom JC, Janson AA, Ginjaar IB, et al. Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med 2007;357(26):2677-86
   PubMed Web of Science ®Google Scholar
• Hoffman EP. Skipping toward personalized molecular medicine. N Engl J Med 2007;357(26):2719-22
   PubMed Web of Science ®Google Scholar
• Beroud C, Tuffery-Giraud S, Matsuo M, et al. Multiexon skipping leading to an artificial DMD protein lacking amino acids from exons 45 through 55 could rescue up to 63% of patients with Duchenne muscular dystrophy. Hum Mutat 2007;28(2):196-202
   PubMed Web of Science ®Google Scholar
• Fall AM, Johnsen R, Honeyman K, et al. Induction of revertant fibres in the mdx mouse using antisense oligonucleotides. Genet Vaccines Ther 2006;4:3. Published online 24 May 2006, doi:10.1186/1479-0556-4-3
   PubMedGoogle Scholar
• Aartsma-Rus A, Kaman WE, Weij R, et al. Exploring the frontiers of therapeutic exon skipping for Duchenne muscular dystrophy by double targeting within one or multiple exons. Mol Ther 2006;14(3):401-7
   PubMed Web of Science ®Google Scholar
• van Vliet L, de Winter CL, van Deutekom JC, et al. Assessment of the feasibility of exon 45–55 multiexon skipping for Duchenne muscular dystrophy. BMC Med Genet 2008;9:105. Published online 1 December 2008, doi:10.1186/1471-2350-9-105
   PubMed Web of Science ®Google Scholar
• Gebski BL, Mann CJ, Fletcher S, Wilton SD. Morpholino antisense oligonucleotide induced dystrophin exon 23 skipping in mdx mouse muscle. Hum Mol Genet 2003;12(15):1801-11
   PubMed Web of Science ®Google Scholar
• Malerba A, Thorogood FC, Dickson G, et al. Dosing regimen has a significant impact on the efficiency of morpholino oligomer-induced exon skipping in mdx mice. Hum Gene Ther 2009 [Epub ahead of print]
   PubMedGoogle Scholar
• Mcclorey G, Fall AM, Moulton HM, et al. Induced dystrophin exon skipping in human muscle explants. Neuromuscul Disord 2006;16(9-10):583-90
   PubMed Web of Science ®Google Scholar
• Heemskerk HA, de Winter CL, de Kimpe SJ, et al. In vivo comparison of 2′-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping. J Gene Med 2009;11(3):257-66
   PubMed Web of Science ®Google Scholar
• Fletcher S, Honeyman K, Fall AM, et al. Morpholino oligomer-mediated exon skipping averts the onset of dystrophic pathology in the mdx mouse. Mol Ther 2007;15(9):1587-92
   PubMed Web of Science ®Google Scholar
• Moulton HM, Fletcher S, Neuman BW, et al. Cell-penetrating peptide-morpholino conjugates alter pre-mRNA splicing of DMD (Duchenne muscular dystrophy) and inhibit murine coronavirus replication in vivo. Biochem Soc Trans 2007;35(Pt 4):826-8
   PubMed Web of Science ®Google Scholar
• Jearawiriyapaisarn N, Moulton HM, Buckley B, et al. Sustained dystrophin expression induced by peptide-conjugated morpholino oligomers in the muscles of mdx mice. Mol Ther 2008;16(9):1624-9
   PubMed Web of Science ®Google Scholar
• Vacek M, Sazani P, Kole R. Antisense-mediated redirection of mRNA splicing. Cell Mol Life Sci 2003;60(5):825-33
   PubMed Web of Science ®Google Scholar
• De Angelis FG, Sthandier O, Berarducci B, et al. Chimeric snRNA molecules carrying antisense sequences against the splice junctions of exon 51 of the dystrophin pre-mRNA induce exon skipping and restoration of a dystrophin synthesis in Δ48–50 DMD cells. Proc Natl Acad Sci USA 2002;99(14):9456-61
   PubMed Web of Science ®Google Scholar
• Zhuang Y, Weiner AM. A compensatory base change in U1 snRNA suppresses a 5′ splice site mutation. Cell 1986;46(6):827-35
   PubMed Web of Science ®Google Scholar
• Denti MA, Incitti T, Sthandier O, et al. Long-term benefit of adeno-associated virus/antisense-mediated exon skipping in dystrophic mice. Hum Gene Ther 2008;19(6):601-8
   PubMed Web of Science ®Google Scholar
• Denti MA, Rosa A, D'Antona G, et al. Body-wide gene therapy of Duchenne muscular dystrophy in the mdx mouse model. Proc Natl Acad Sci USA 2006;103(10):3758-63
   PubMed Web of Science ®Google Scholar
• Goyenvalle A, Vulin A, Fougerousse F, et al. Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping. Science 2004;306(5702):1796-9
   PubMed Web of Science ®Google Scholar
• Igoucheva O, Alexeev V, Yoon K. Targeted gene correction by small single-stranded oligonucleotides in mammalian cells. Gene Ther 2001;8(5):391-9
   PubMed Web of Science ®Google Scholar
• Tagalakis AD, Graham IR, Riddell DR, et al. Gene correction of the apolipoprotein (Apo) E2 phenotype to wild-type ApoE3 by in situ chimeraplasty. J Biol Chem 2001;276(16):13226-30
   PubMed Web of Science ®Google Scholar
• Bertoni C. Oligonucleotide-mediated gene editing for neuromuscular disorders. Acta Myol 2005;24(3):194-201
   PubMedGoogle Scholar
• Bertoni C, Morris GE, Rando TA. Strand bias in oligonucleotide-mediated dystrophin gene editing. Hum Mol Genet 2005;14(2):221-33
   PubMed Web of Science ®Google Scholar
• Liu CM, Liu DP, Liang CC. Oligonucleotide-mediated gene repair at DNA level: the potential applications for gene therapy. J Mol Med 2002;80(10):620-8
   PubMed Web of Science ®Google Scholar
• Igoucheva O, Alexeev V, Yoon K. Differential cellular responses to exogenous DNA in mammalian cells and its effect on oligonucleotide-directed gene modification. Gene Ther 2006;13(3):266-75
   PubMed Web of Science ®Google Scholar
• Liu X, Jiang Q, Mansfield SG, et al. Partial correction of endogenous ΔF508 CFTR in human cystic fibrosis airway epithelia by spliceosome-mediated RNA trans-splicing. Nat Biotechnol 2002;20(1):47-52
   PubMed Web of Science ®Google Scholar
• Chao H, Mansfield SG, Bartel RC, et al. Phenotype correction of hemophilia A mice by spliceosome-mediated RNA trans-splicing. Nat Med 2003;9(8):1015-9
   PubMed Web of Science ®Google Scholar
• Tahara M, Pergolizzi RG, Kobayashi H, et al. Trans-splicing repair of CD40 ligand deficiency results in naturally regulated correction of a mouse model of hyper-IgM X-linked immunodeficiency. Nat Med 2004;10(8):835-41
   PubMed Web of Science ®Google Scholar
• Chen HY, Kathirvel P, Yee WC, Lai PS. Correction of dystrophia myotonica type 1 pre-mRNA transcripts by artificial trans-splicing. Gene Ther 2009;16(2):211-7
   PubMed Web of Science ®Google Scholar
• Mansfield SG, Kole J, Puttaraju M, et al. Repair of CFTR mRNA by spliceosome-mediated RNA trans-splicing. Gene Ther 2000;7(22):1885-95
   PubMed Web of Science ®Google Scholar
• Lan N, Howrey RP, Lee SW, et al. Ribozyme-mediated repair of sickle β-globin mRNAs in erythrocyte precursors. Science 1998;280(5369):1593-6
   PubMed Web of Science ®Google Scholar
• Phylactou LA, Kilpatrick MW, Wood MJ. Ribozymes as therapeutic tools for genetic disease. Hum Mol Genet 1998;7(10):1649-53
   PubMed Web of Science ®Google Scholar
• Quenneville SP, Chapdelaine P, Skuk D, et al. Autologous transplantation of muscle precursor cells modified with a lentivirus for muscular dystrophy: human cells and primate models. Mol Ther 2007;15(2):431-8
   PubMed Web of Science ®Google Scholar
• Ikemoto M, Fukada S, Uezumi A, et al. Autologous transplantation of SM/C-2.6+ satellite cells transduced with micro-dystrophin CS1 cDNA by lentiviral vector into mdx mice. Mol Ther 2007;15(12):2178-85
   PubMed Web of Science ®Google Scholar
• Quenneville SP, Chapdelaine P, Rousseau J, Tremblay JP. Dystrophin expression in host muscle following transplantation of muscle precursor cells modified with the phiC31 integrase. Gene Ther 2007;14(6):514-22
   PubMed Web of Science ®Google Scholar
• Skuk D, Goulet M, Roy B, et al. First test of a “high-density injection” protocol for myogenic cell transplantation throughout large volumes of muscles in a Duchenne muscular dystrophy patient: eighteen months follow-up. Neuromuscul Disord 2007;17(1):38-46
   PubMed Web of Science ®Google Scholar
• Skuk D, Roy B, Goulet M, et al. Dystrophin expression in myofibers of Duchenne muscular dystrophy patients following intramuscular injections of normal myogenic cells. Mol Ther 2004;9(3):475-82
   PubMed Web of Science ®Google Scholar
• Benchaouir R, Meregalli M, Farini A, et al. Restoration of human dystrophin following transplantation of exon-skipping-engineered DMD patient stem cells into dystrophic mice. Cell Stem Cell 2007;1(6):646-57
   PubMed Web of Science ®Google Scholar
• Meregalli M, Farini A, Torrente Y. Combining stem cells and exon skipping strategy to treat muscular dystrophy. Expert Opin Biol Ther 2008;8(8):1051-61
   PubMed Web of Science ®Google Scholar
• Torrente Y, Belicchi M, Marchesi C, et al. Autologous transplantation of muscle-derived CD133+ stem cells in Duchenne muscle patients. Cell Transplant 2007;16(6):563-77
   PubMed Web of Science ®Google Scholar
• Dellavalle A, Sampaolesi M, Tonlorenzi R, et al. Pericytes of human skeletal muscle are myogenic precursors distinct from satellite cells. Nat Cell Biol 2007;9(3):255-67
   PubMed Web of Science ®Google Scholar
• Sampaolesi M, Blot S, D'Antona G, et al. Mesoangioblast stem cells ameliorate muscle function in dystrophic dogs. Nature 2006;444(7119):574-9
   PubMed Web of Science ®Google Scholar
• Goncalves MA, Swildens J, Holkers M, et al. Genetic complementation of human muscle cells via directed stem cell fusion. Mol Ther 2008;16(4):741-8
   PubMed Web of Science ®Google Scholar
• Kimura E, Han JJ, Li S, et al. Cell-lineage regulated myogenesis for dystrophin replacement: a novel therapeutic approach for treatment of muscular dystrophy. Hum Mol Genet 2008;17(16):2507-17
   PubMed Web of Science ®Google Scholar
• Chaouch S, Mouly V, Goyenvalle A, et al. Immortalized skin fibroblasts expressing conditional MyoD as a renewable and reliable source of converted human muscle cells to assess therapeutic strategies for muscular dystrophies: validation of an exon skipping approach to restore dystrophin in DMD cells. Hum Gene Ther 2009 published online 9 April 2009. Available from: http://www.liebertonline.com/doi/pdf/10.1089/hum.2008.163 [Last accessed 19 May 2009]
   PubMedGoogle Scholar
• Mackenzie TC, Kobinger GP, Louboutin JP, et al. Transduction of satellite cells after prenatal intramuscular administration of lentiviral vectors. J Gene Med 2005;7(1):50-8
   PubMed Web of Science ®Google Scholar
• Kobinger GP, Louboutin JP, Barton ER, et al. Correction of the dystrophic phenotype by in vivo targeting of muscle progenitor cells. Hum Gene Ther 2003;14(15):1441-9
   PubMed Web of Science ®Google Scholar
• Gargioli C, Coletta M, De Grandis F, et al. PlGF-MMP-9-expressing cells restore microcirculation and efficacy of cell therapy in aged dystrophic muscle. Nat Med 2008;14(9):973-8
   PubMed Web of Science ®Google Scholar
• Laumonier T, Yang S, Konig S, et al. Lentivirus mediated HO-1 gene transfer enhances myogenic precursor cell survival after autologous transplantation in pig. Mol Ther 2008;16(2):404-10
   PubMed Web of Science ®Google Scholar
• Benabdallah BF, Bouchentouf M, Rousseau J, et al. Inhibiting myostatin with follistatin improves the success of myoblast transplantation in dystrophic mice. Cell Transplant 2008;17(3):337-50
   PubMed Web of Science ®Google Scholar
• Bouchentouf M, Benabdallah BF, Bigey P, et al. Vascular endothelial growth factor reduced hypoxia-induced death of human myoblasts and improved their engraftment in mouse muscles. Gene Ther 2008;15(6):404-14
   PubMed Web of Science ®Google Scholar
• Li ZB, Kollias HD, Wagner KR. Myostatin directly regulates skeletal muscle fibrosis. J Biol Chem 2008;283(28):19371-8
   PubMed Web of Science ®Google Scholar
• Lee SJ, Mcpherron AC. Regulation of myostatin activity and muscle growth. Proc Natl Acad Sci USA 2001;98(16):9306-11
   PubMed Web of Science ®Google Scholar
• Minetti GC, Colussi C, Adami R, et al. Functional and morphological recovery of dystrophic muscles in mice treated with deacetylase inhibitors. Nat Med 2006;12(10):1147-50
   PubMed Web of Science ®Google Scholar
• Bogdanovich S, Krag TO, Barton ER, et al. Functional improvement of dystrophic muscle by myostatin blockade. Nature 2002;420(6914):418-21
   PubMed Web of Science ®Google Scholar
• Bogdanovich S, Mcnally EM, Khurana TS. Myostatin blockade improves function but not histopathology in a murine model of limb-girdle muscular dystrophy 2C. Muscle Nerve 2008;37(3):308-16
   PubMed Web of Science ®Google Scholar
• Wagner KR, Fleckenstein JL, Amato AA, et al. A Phase I/IItrial of MYO-029 in adult subjects with muscular dystrophy. Ann Neurol 2008;63(5):561-71
   PubMed Web of Science ®Google Scholar
• Morrison BM, Lachey JL, Warsing LC, et al. A soluble activin type IIB receptor improves function in a mouse model of amyotrophic lateral sclerosis. Exp Neurol 2009;217(2):258-68
   PubMed Web of Science ®Google Scholar
• Ohsawa Y, Hagiwara H, Nakatani M, et al. Muscular atrophy of caveolin-3-deficient mice is rescued by myostatin inhibition. J Clin Invest 2006;116(11):2924-34
   PubMed Web of Science ®Google Scholar
• Bogdanovich S, Perkins KJ, Krag TO, et al. Myostatin propeptide-mediated amelioration of dystrophic pathophysiology. Faseb J 2005;19(6):543-9
   PubMed Web of Science ®Google Scholar
• Krivickas LS, Walsh R, Amato AA. Single muscle fiber contractile properties in adults with muscular dystrophy treated with MYO-029. Muscle Nerve 2009;39(1):3-9
   PubMed Web of Science ®Google Scholar
• Qiao C, Li J, Zheng H, et al. Hydrodynamic limb vein injection of adeno-associated virus serotype 8 carrying canine myostatin propeptide gene into normal dogs enhances muscle growth. Hum Gene Ther 2009;20(1):1-10
   PubMed Web of Science ®Google Scholar
• Bartoli M, Poupiot J, Vulin A, et al. AAV-mediated delivery of a mutated myostatin propeptide ameliorates calpain 3 but not α-sarcoglycan deficiency. Gene Ther 2007;14(9):733-40
   PubMed Web of Science ®Google Scholar
• Qiao C, Li J, Jiang J, et al. Myostatin propeptide gene delivery by adeno-associated virus serotype 8 vectors enhances muscle growth and ameliorates dystrophic phenotypes in mdx mice. Hum Gene Ther 2008;19(3):241-54
   PubMed Web of Science ®Google Scholar
• Foster K, Graham IR, Otto A, et al. Adeno-associated virus-8-mediated intravenous transfer of myostatin propeptide leads to systemic functional improvements of slow but not fast muscle. Rejuvenation Res 2009;12(2):85-94
   PubMed Web of Science ®Google Scholar
• Haidet AM, Rizo L, Handy C, et al. Long-term enhancement of skeletal muscle mass and strength by single gene administration of myostatin inhibitors. Proc Natl Acad Sci USA 2008;105(11):4318-22
   PubMed Web of Science ®Google Scholar
• Magee TR, Artaza JN, Ferrini MG, et al. Myostatin short interfering hairpin RNA gene transfer increases skeletal muscle mass. J Gene Med 2006;8(9):1171-81
   PubMed Web of Science ®Google Scholar
• Kinouchi N, Ohsawa Y, Ishimaru N, et al. Atelocollagen-mediated local and systemic applications of myostatin-targeting siRNA increase skeletal muscle mass. Gene Ther 2008;15(15):1126-30
   PubMed Web of Science ®Google Scholar
• Nakatani M, Takehara Y, Sugino H, et al. Transgenic expression of a myostatin inhibitor derived from follistatin increases skeletal muscle mass and ameliorates dystrophic pathology in mdx mice. Faseb J 2008;22(2):477-87
   PubMed Web of Science ®Google Scholar
• Romero NB, Braun S, Benveniste O, et al. Phase I study of dystrophin plasmid-based gene therapy in Duchenne/Becker muscular dystrophy. Hum Gene Ther 2004;15(11):1065-76
   PubMed Web of Science ®Google Scholar
• Available from: www.mda.org
   Google Scholar
• Lee SJ, Reed LA, Davies MV, et al. Regulation of muscle growth by multiple ligands signaling through activin type II receptors. Proc Natl Acad Sci USA 2005;102(50):18117-22
   PubMed Web of Science ®Google Scholar
• Rodino-Klapac LR, Haidet AM, Kota J, et al. Inhibition of myostatin with emphasis on follistatin as a therapy for muscle disease. Muscle & Nerve 2009;39(3):283-96
   PubMed Web of Science ®Google Scholar
• Benabdallah BF, Bouchentouf M, Rousseau J, et al. Inhibiting myostatin with follistatin improves the success of myoblast transplantation in dystrophic mice. Cell Transplant 2008;16:337-50
   Google Scholar
• Liu CM, Yang Z, Liu CW, et al. Myostatin antisense RNA-mediated muscle growth in normal and cancer cachexia mice. Gene Ther 2008;15(3):155-60
   PubMed Web of Science ®Google Scholar